

Atrium Health Infusion Center

Signature:

Referral Status:	☐ New Start ☐ Order Change ☐ Renewal	
Preferred Location:	Atrium Health Infusion Center Concord Fax: 704-468-3401	
	Atrium Health Infusion Center Pineville Fax: 704-468-3401	
	Atrium Health Infusion Center Southpark Fax: 704-468-3401	
	Atrium Health Infusion Center Huntersville Fax: 704-468-3401	
	Atrium Health Infusion Center Kenilworth, a facility of CMC Fax: 704-512-5390	
	Atrium Health Infusion Center Abbey Place, a facility of CMC Fax: 704-512-5390	
	☐ Atrium Health Infusion Center Cabarrus, a facility of CMC Fax: 704-512-5390	

Ultomiris® (ravulizumab) Infusion Order (Revised 11/10/2025)

All orders with a √ will be placed. MRN: Patient Name Date of Birth: Address: City: State: Zip Code: Allergies: (please list all allergies or attach list) □ NKDA nplete the 2nd and/or 3rd Digits of the ICD-10 ☐ D59.5 - Paroxysmal nocturnal hemoglobinuria☐ D59.30 - Hemolytic Uremic Syndrome G70.01 - Myastenia Gravis with acute exacerbation
G70.00 - Myasthenia Gravis without acute exacerbation Other: Patient Demographic Sheet If the patient is new to the ordered therapy, indicate washout from previous therapy. Copy of Insurance Card (front and back) Most Recent Labs (must include labs pertinent to medication ordered) ■ No Washout Needed Consult Note or last 2 Office Visits with referring provider or APP If the patient is currently on the therapy, indicate date of last infusion: Complete Medication List -Next infusion due date: Include all tried and failed meds If this is an order change only, indicate if the current therapy should be administered until insurance approval is received for the new request. Diagnostic Studies Pertinent to Medication Ordered ☐ Yes ☐ No Urine Pregnancy Test prior to each infusion on all females of reproductive potential - POC HCG Qualitative, Urine Hold treatment and notify provider IF: - Temperature is GREATER THAN 100oF; - Patient complains of symptoms of acute viral or bacterial infection; - Patient is taking an antibiotic for current infection. Required lab results: Urine Pregnancy Test. (fax labs with order) - Hold Tx and Notify Provider IF: - Urine Pregnancy Test: POSITIVE Ravulizumab is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Ultomiris REMS, healthcare providers must enroll in the program. Enrollment in the $Ultomiris\ REMS\ program\ and\ additional\ information\ are\ available\ from\ the\ manufacturer\ (1-888-765-4747)\ OR\ at\ ultsorems.com$ Immunize patients with meningococcal vaccines at least 2 weeks PRIOR to the first dose of ravulizumab, unless the risks of delaying ravulizumab therapy outweigh the risk of developing a meningococcal infection. If not previously administered give BOTH: Quadrivalent meningococcal vaccine (Menveo) IM once - Meningococcal group B vaccine (Bexsero) IM once May also consider vaccinations for other encapsulated organisms: - Haemophilus B conjugate vaccine (ActHIB) IM once - Pneumococcal vaccine polyvalent (Pneumovax 23) IM once If meningococcal vaccines administered LESS THAN 2 weeks BEFORE the FIRST dose of ravulizumab, antimicrobial prophylaxis is suggested. Start PIV/Access CVC and flush device per approved Atrium Health protocol. Obtain vital signs PRE-treatment, POST-treatment, and at discharge. Monitor for signs of reaction or side effects for 60 minutes POST-treatment. Pre-Medications:

Acetaminophen (Tylenol) 650mg PO ONCE Diphenhydramine (Benadryl) 25mg PO ONCE Diphenhydramine (Benadryl) 25mg IV ONCE
Control Loratadine (Claritin) 10mg PO ONCE Methylprednisolone Sodium Succinate (Solu-Medrol) 125mg IV ONCE Loading Dose: Ravulizumab (Ultomiris) Week 0 2700mg (60 - LESS THAN 100kg) IV 2400mg (40 - LESS THAN 60kg) IV 3000mg (100kg or more) IV Maintenance Dose: Week 2, then every 8 weeks 3300mg (60 - LESS THAN 100kg) IV 3000mg (40 - LESS THAN 60kg) IV 3600mg (100kg or more) IV Acetaminophen (Tylenol) 650mg PO ONCE PRN mild pain (1-3) or moderate pain (4-6). Give first if not given as a pre-medication. Ibuprofen (Motrin) 800mg PO ONCE PRN mild pain (1-3) or moderate pain (4-6). Give second after acetaminophen. Ondansetron (Zofran) 4mg IV ONCE PRN nausea/vomiting. Initiate Atrium Health approved hypersensitivity protocol in the event of an acute adverse or anaphylactic infusion/injection reaction. The hypersensitivity protocol can be found on the Atrium Health Infusion Center website at atriumhealth.org/infusion. Provider Name: Phone: Fax: Practice Name: NPI: Address: Office Contact: City, State, Zip: Office Contact Phone Number: Physician Sign

Date: